ANIX

Anixa Biosciences, Inc.

2.70

USD

ANIX Earnings Reports

Positive Surprise Ratio

ANIX beat 21 of 30 last estimates.

70%

Next Report

Date of Next Report

May 26, 2026

Estimate for Q2 26 (Revenue/ EPS)

-$0.08

Implied change from Q1 26 (Revenue/ EPS)

Implied change from Q2 25 (Revenue/ EPS)

-11.11%

Anixa Biosciences, Inc. earnings per share and revenue

On Mar 09, 2026, ANIX reported earnings of -0.08 USD per share (EPS) for Q1 26, beating the estimate of -0.09 USD, resulting in a 17.44% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).

Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Anixa Biosciences, Inc.'s earnings and revenue for the latest quarter Q1 2026?

For Q1 2026, Anixa Biosciences, Inc. reported EPS of -$0.08, beating estimates by 17.44%, and revenue of $0.00, 0% as expectations.

How did the market react to Anixa Biosciences, Inc.'s Q1 2026 earnings?

The stock price moved -- 0%, changed from $2.98 before the earnings release to $2.98 the day after.

When is Anixa Biosciences, Inc. expected to report next?

The next earning report is scheduled for May 26, 2026.

What are the forecasts for Anixa Biosciences, Inc.'s next earnings report?

Based on 5 analysts, Anixa Biosciences, Inc. is expected to report EPS of -$0.08 and revenue of -- for Q2 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.